scholarly journals Marginal bone loss around implants placed in maxillary native bone or grafted sinuses: a retrospective cohort study

2013 ◽  
Vol 25 (3) ◽  
pp. 378-384 ◽  
Author(s):  
P. Galindo-Moreno ◽  
A. Fernández-Jiménez ◽  
G. Avila-Ortiz ◽  
F.J. Silvestre ◽  
P. Hernández-Cortés ◽  
...  
Keyword(s):  
Cohort Study ◽  
Bone Loss ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Marginal Bone Loss ◽  
Native Bone

Retrospective Cohort Study on the Influence of Bone Remodeling on Marginal Bone Loss and Peri-implantitis Around Immediately Loaded Implants Supporting Complete-Arch Restorations

2021 ◽  
Vol 36 (6) ◽  
pp. 1165-1172
Author(s):  
Alba Sánchez-Torres ◽  
Iñaki Cercadillo-Ibarguren ◽  
Marta Moragón-Rodríguez ◽  
Rui Figueiredo ◽  
Eduard Valmaseda-Castellón ◽  
...  
Keyword(s):  
Cohort Study ◽  
Bone Loss ◽  
Bone Remodeling ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Marginal Bone Loss

scholarly journals Annual alveolar bone loss in older adults taking oral bisphosphonate: a retrospective cohort study

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Mohammad Helmi ◽  
Sara AlOsaimy ◽  
J. Max Goodson ◽  
Hatice Hasturk ◽  
Zuhair S. Natto
Keyword(s):  
Older Adults ◽  
Cohort Study ◽  
Bone Loss ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Alveolar Bone ◽  
Periodontal Diseases ◽  
Alveolar Bone Loss ◽  
Oral Bisphosphonate ◽  
Associated Risk Factors

Abstract Background Although several studies assessed the effect of bisphosphonate (BIS) administration on alveolar bone loss, this relationship has not been fully investigated using longitudinal analysis. The aim of the this article is to predict annual alveolar bone loss in a subpopulation of older adults patients who were taking oral bisphosphonate (BIS), adjusting for systemic diseases and associated risk factors. Methods This is a retrospective cohort study. We identified all subjects who reported receiving oral bisphosphonate from 2008 to 2015 (N = 30) using the electronic health records of each patient to identify suitable radiographs for analysis. For the longitudinal data analysis, 26 subjects were eligible for inclusion, having at least two exposures of the complete mouth set or repeated bitewing radiographs at least a one-year interval; they were then matched on age and sex to another 26 patients who did not report receiving bisphosphonate at any point of their life. Results Mild periodontitis was higher in the BIS group compared to the no BIS group; however, moderate periodontitis was higher in the no BIS group. For those who did not take oral BIS, change over time was not significant after the two-year period. However, the BIS group had experienced 0.088 mm more bone loss compared to the no BIS group (95% CI: 0.001, 0.176. P-value = 0.048), adjusting for all other variables included in the model. Conclusion The group that reported receiving oral bisphosphonates showed no improvement in maintaining alveolar bone level, and the use of oral BIS may not be effective in reducing annual alveolar bone loss; however, emerging evidence is promising for the use of bisphosphonate as an adjunctive local delivery medication for the management of periodontal diseases.

scholarly journals Alveolar Bone Loss, Tooth Loss and Oral Cancer Mortality in Older Patients: A Retrospective Cohort Study

2020 ◽  
Vol Volume 15 ◽  
pp. 1419-1425
Author(s):  
Yifeng Qian ◽  
Huiting Yu ◽  
Weijun Yuan ◽  
Jiaqing Wu ◽  
Qingyu Xu ◽  
...  
Keyword(s):  
Cohort Study ◽  
Oral Cancer ◽  
Bone Loss ◽  
Retrospective Cohort Study ◽  
Cancer Mortality ◽  
Older Patients ◽  
Retrospective Cohort ◽  
Tooth Loss ◽  
Alveolar Bone ◽  
Alveolar Bone Loss

Occurrence of Progressive Bone Loss Around Anodized Surface Implants and Resorbable Blasting Media Implants: A Retrospective Cohort Study

2017 ◽  
Vol 88 (4) ◽  
pp. 329-337 ◽  
Author(s):  
Hee-Chang Kim ◽  
Shin-Young Park ◽  
Min-Su Han ◽  
Yong-Moo Lee ◽  
Young Ku ◽  
...  
Keyword(s):  
Cohort Study ◽  
Bone Loss ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort

scholarly journals Annual Alveolar Bone Loss in Older Adults Taking Oral Bisphosphonate: A Retrospective Cohort Study

2019 ◽  
Author(s):  
Mohammad Helmi ◽  
Sara AlOsaimy ◽  
J. Max Goodson ◽  
Hatice Hasturk ◽  
Zuhair S. Natto
Keyword(s):  
Older Adults ◽  
Cohort Study ◽  
Bone Loss ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Alveolar Bone ◽  
Periodontal Diseases ◽  
Alveolar Bone Loss ◽  
P Value ◽  
Oral Bisphosphonate

Abstract Background: Although several studies assessed the effect of bisphosphonate (BIS) administration on alveolar bone loss, this relationship has not been fully investigated using longitudinal analysis. The aim of the this article is to predict annual alveolar bone loss in a subpopulation of older adults patients who were taking oral bisphosphonate (BIS), adjusting for systemic diseases and associated risk factors. Methods: This is a retrospective cohort study. We identified all subjects who reported receiving oral bisphosphonate from 2008–2015 (N=30) using the electronic health records of each patient to identify suitable radiographs for analysis. For the longitudinal data analysis, 26 subjects were eligible for inclusion, having at least two exposures of the complete mouth set or repeated bitewing radiographs at least a one-year interval; they were then matched on age and sex to another 26 patients who did not report receiving bisphosphonate at any point of their life. Results: Mild periodontitis was higher in the BIS group compared to the no BIS group; however, moderate periodontitis was higher in the no BIS group. For those who did not take oral BIS, change over time was not significant after the two-year period. However, the BIS group had experienced 0.088 mm more bone loss compared to the no BIS group (95% CI: 0.001, 0.176. P-value = 0.048), adjusting for all other variables included in the model. Conclusion: The group that reported receiving oral bisphosphonates showed no improvement in maintaining alveolar bone level, and the use of oral BIS may not be effective in reducing annual alveolar bone loss; however, emerging evidence is promising for the use of bisphosphonate as an adjunctive local delivery medication for the management of periodontal diseases.

Sign in / Sign up

Export Citation Format

Share Document